Tcr2 Therapeutics - TCRR STOCK NEWS

TCR2 Therapeutics Inc. (Nasdaq: TCRR) reported Q1 2021 financials showing a cash position of $333.3 million, up from $228.0 million at the end of 2020. The net loss increased to $21.5 million, attributed mainly to higher personnel costs. The company is advancing its gavo-cel therapy and plans a commercial-scale cGMP facility in Maryland by 2023. R&D expenses rose to $15.9 million due to ongoing trials. TCR2 aims to file IND for TC-510 and present additional clinical data in 2021, anticipating cash sufficiency through 2023.

CAMBRIDGE, Mass., April 29, 2021 - TCR² Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 11:20 AM E.T. The event will be held virtually, and a live webcast will be accessible on the Company’s Investors page. TCR² focuses on developing novel T cell therapies targeting solid tumors and hematological malignancies, including gavo-cel for mesothelin-positive cancers and TC-110 for CD19-positive leukemias.

TCR2 Therapeutics Inc. (TCRR) announced clinical data from the Phase 1/2 trial of gavo-cel, a T cell therapy for mesothelin-expressing solid tumors, which was presented at the AACR Virtual Annual Meeting. In the trial, 8 patients showed a median transduction efficiency of 49% and a CD4:CD8 ratio of 7.15. Initial results suggest manageable toxicity and clinical benefit. The company plans to invest in its solid tumor pipeline, including CD70-targeting therapies. Gavo-cel aims to address patients with advanced cancer who have exhausted existing treatment options.

On April 8, 2021, TCR² Therapeutics (Nasdaq: TCRR) announced that CFO Ian Somaiya will present company progress at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:00 AM E.T. The presentation will be hosted on a virtual platform, with a live webcast available on the company's Investor page. TCR² focuses on developing novel T cell therapies for cancer patients, showcasing promising preclinical results with their TRuC^®-T cells. The company's lead candidates, gavo-cel and TC-110, are in Phase 1/2 trials for various cancers.

TCR² Therapeutics Inc. (TCRR) has announced a long-term lease for an 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland. This state-of-the-art facility is designed for commercial-scale production of gavo-cel, aimed at treating thousands of cancer patients annually, with operations expected to begin in 2023. The company has also appointed Aaron Vernon as Vice President of Technical Operations to enhance manufacturing capabilities. The new site will optimize production while reducing costs, allowing TCR² to effectively manage its supply chain.

TCR2 Therapeutics Inc. (TCRR) reported a transformative year in 2020, highlighting a 38% Overall Response Rate in the Phase 1 trial of gavo-cel for solid tumors. The company raised $140 million in a follow-on offering, strengthening its cash position to $228 million, extending its runway into 2024. R&D expenses rose to $52 million, contributing to a net loss of $67.1 million, driven by increased personnel costs. TCR2 plans to accelerate gavo-cel development and provide updates at AACR 2021, emphasizing its commitment to advancing innovative cancer therapies.

TCR² Therapeutics Inc. (Nasdaq: TCRR) announced three e-poster presentations showcasing new clinical data from the Phase 1 trial of gavo-cel for treatment-refractory mesothelin-expressing solid tumors, to be presented at the AACR Virtual Annual Meeting from April 10-15, 2021. Key presentations include data on gavo-cel's preliminary safety and efficacy, and engineering off-the-shelf TRuC-T cells. The trial aims to leverage TRuC technology for enhanced anti-tumor activity and lower cytokine release compared to traditional CAR-T cells.

On March 3, 2021, TCR² Therapeutics (Nasdaq: TCRR) announced upcoming presentations at two virtual conferences in March. Ian Somaiya, CFO, will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 am ET. Somaiya will also join Robert Hofmeister, CSO, for a fireside chat at the 33rd Annual Roth Conference on March 17, 2021, at 11:00 am ET. Live webcasts will be available on the company's Investors page, with archived replays for at least 30 days.

TCR² Therapeutics (Nasdaq: TCRR) announced a participation of Ian Somaiya and Alfonso Quintás-Cardama in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 AM ET.

This fireside chat will be accessible via a live webcast on the Company's Investors page, with an archived replay available for 30 days post-event. TCR² focuses on innovative T cell therapies for cancer, including its lead candidates gavo-cel for solid tumors and TC-110 for hematological malignancies.